Schering-Plough files asthma combination in Europe
27 August 2009
James Mills
Please Login to read the full article.
27 August 2009
James Mills
james.mills@informa.com
The
European Medicines Agency (EMEA) has agreed to review
Schering-Plough's centralised EU application for approval to market a fixed-dose inhaled combination of its corticosteroid Asmanex (mometasone furoate) and the long-acting beta-2 agonist formoterol fumarate (Novartis's Foradil) for the maintenance...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Pearl seeks partner for COPD LAMA after positive Phase IIb results
- Pearl on track for 2012 pivotal COPD studies thanks to Phase IIb progress
- FDA queries need for higher dose of Novartis LABA COPD drug
- GSK sees £3 billion wiped off value in response to mixed Phase III Relovair data
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
